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Abstract
Background: Treatment efficacy of physical agents in osteoarthritis of the knee (OAK) pain has
been largely unknown, and this systematic review was aimed at assessing their short-term efficacies
for pain relief.
Methods: Systematic review with meta-analysis of efficacy within 1–4 weeks and at follow up at
1–12 weeks after the end of treament.
Results: 36 randomised placebo-controlled trials (RCTs) were identified with 2434 patients where
1391 patients received active treatment. 33 trials satisfied three or more out of five methodological
criteria (Jadad scale). The patient sample had a mean age of 65.1 years and mean baseline pain of
62.9 mm on a 100 mm visual analogue scale (VAS). Within 4 weeks of the commencement of
treatment manual acupuncture, static magnets and ultrasound therapies did not offer statistically
significant short-term pain relief over placebo. Pulsed electromagnetic fields offered a small
reduction in pain of 6.9 mm [95% CI: 2.2 to 11.6] (n = 487). Transcutaneous electrical nerve
stimulation (TENS, including interferential currents), electro-acupuncture (EA) and low level laser
therapy (LLLT) offered clinically relevant pain relieving effects of 18.8 mm [95% CI: 9.6 to 28.1] (n
= 414), 21.9 mm [95% CI: 17.3 to 26.5] (n = 73) and 17.7 mm [95% CI: 8.1 to 27.3] (n = 343) on
VAS respectively versus placebo control. In a subgroup analysis of trials with assumed optimal
doses, short-term efficacy increased to 22.2 mm [95% CI: 18.1 to 26.3] for TENS, and 24.2 mm
[95% CI: 17.3 to 31.3] for LLLT on VAS. Follow-up data up to 12 weeks were sparse, but positive
effects seemed to persist for at least 4 weeks after the course of LLLT, EA and TENS treatment
was stopped.
Conclusion: TENS, EA and LLLT administered with optimal doses in an intensive 2–4 week
treatment regimen, seem to offer clinically relevant short-term pain relief for OAK.
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Osteoarthritis of the knee (OAK) is the most common
type of osteoarthritis (OA)[1], and its prevalence is rising
in parallel with the increasing age of the population [2].
The condition is associated with pain and inflammation
of the joint capsule [3], impaired muscular stabilisation
[4,5], reduced range of motion [6], and functional disabil-
ity.
European League Against Rheumatism (EULAR) recom-
mendations state that both pharmacological and non-
pharmacologial interventions are needed for optimal
treatment of OAK with at least 33 potentially effective
interventions at the clinicians' disposal [7]. Ten of these
interventions are listed as non-pharmacological and 5 of
these non-pharmacological interventions are physical
agents: acupuncture; low level laser therapy (LLLT);
pulsed electromagnetic fields (PEMF, including shortwave
therapy SWT); transcutaneous electrical nerve stimulation
(TENS), and ultrasound (US). While paracetamol, opio-
ids and coxibs receive recommendations based on the sec-
ond highest level of evidence (1B), no physical agents are
recommended in spite of being listed as having the same
evidence level (1B).
Inadequate dosageand inappropriate procedural tech-
nique can contaminate the findings of RCTs of physical
agents but the EULAR analysis did not account for this.
Recent findings suggest that most physical agents exhibit
fairly distinct dose-response patterns, and failure to
account for adequacy of TENS [8] and LLLT [9] interven-
tions can markedly reduce ES estimates. Indeed, evidence-
based guidelines for dosage and treatment procedures and
the conduct of systematic reviews have been published for
LLLT [10], and for acupuncture [11].
An appropriate approach would then be to investigate the
short-term efficacy of physical agents for OAK, for all trials
with each intervention and then to make sub-group anal-
yses for trials according to their compliance with adequate
dosageand procedural recommendations. Consistency in
trial design and in the selection and timing of outcome
measures must be assured to allow for comparison
between interventions [12]. The selected meta-analysis
methodology was identical to that previously used by our
group to assess common pharmacological interventions
for OAK [13].
Methods
Review protocol specification
A detailed review protocol was specified prior to analysis.
This included a sequential three-step reviewing procedure
of 1) harvesting randomised placebo-controlled trials
where patients were treated with specified interventions
for knee ostoarthritis, 2) evaluating their methodological
quality according to predefined criteria, and 3) calculating
their pooled effect as the weighted mean difference
(WMD) in change between intervention and placebo in
mm on a 100 mm visual analogue scale (VAS).
Literature search
A specified literature search was performed from 1966
through April 2006 on Medline, Embase, Cochrane Con-
trolled Trials Register for RCTs, CINAHL, Database of
Abstracts of Reviews of Effectiveness (DARE), Interna-
tional Network of Agencies for Health Technology Assess-
ment (INAHTA) database, The Physiotherapy Evidence
Database (PEDro), National Guideline Clearinghouse
(NGC), PRODIGY Guidance, and NICE (National Insti-
tute for Clinical Excellence). In addition, hand searches
were performed in the journal Laser Therapy from 1994,
and in books of abstracts from congresses arranged after
1990 by the World Confederation of Physical Therapy
and World Association for Laser Therapy.
The following search string was used: Osteoarthritis OR
osteoarthrosis OR knee OR exercise OR electrotherapy OR
laser therapy OR light therapy OR ultrasound OR electros-
timulation OR transcutaneous electrical nerve stimulation
OR electromagnetic AND randomized OR randomised.
In addition, handsearches of national Scandinavian phys-
iotherapy journals, conference abstracts and reference lists
of systematic reviews were performed, and experts in the
field were consulted. No language restrictions were
applied with papers in English, German and Scandinavian
languages eligible for inclusion.
Inclusion criteria
The trials were subjected to 6 inclusion criteria:
1. Diagnosis
A statement in the report that knee osteoarthritis had been
verified by clinical examination according to the Ameri-
can College of Rhematology criteria and/or by x-ray.
2. Symptom duration
More than 3 months.
3. Trial design
Randomised blinded placebo-controlled parallel and
cross-over groups design.
4. Outcome measures
Primary outcome measure: Pain intensity within 4 weeks
of treatment start scored on the Western Ontario and
McMaster Universities osteoarthritis index (WOMAC)
subscale of pain, or on a 100 mm VAS for global or walk-
ing pain.Page 2 of 14
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for the primary outcome measure, at 5–12 weeks follow-
up.
5. Threshold levels for clinical relevance
Mean threshold for OAK patients reporting "minimal
clinical important improvement" has been determined to
19.9 mm on VAS [14]. Likewise, the mean threshold for
inducing a categorical change from "no change" to "slight
improvement" has been determined to be 12.7 mm [15],
while the mean threshold for "minimal perceptible clini-
cal improvement" is determined to be 9.7 mm [16].
6. Intervention groups, including criteria for modality-specific optimal 
dosage
Acupuncture
Interventions which produced somatic stimulation of
'acupuncture points' were included; i.e. manual or electri-
cal dry needling.
Criteria for optimal dose (i.e. compliance with adequate
dosageand procedural recommendations) were: manual
or electrical dry needling of acupuncture 3 or more acu-
puncture points as defined in Traditional Chinese Medi-
cine and performed by an acupuncturist with at least 2
years clinical experience. As it is plausible that manual
acupuncture and electro-acupuncture trigger different bio-
logical mechanisms, we decided to group and assess man-
ual acupuncture and electro-acupuncture separately.
Categorisation as electro-acupuncture demanded electri-
cal current intensity to be at a strong, near noxious level,
which has been shown to be more effective than a low
intensity level [17].
Low level laser therapy (LLLT)
Criteria for optimal dose: GaAs 904 nm infrared pulse
lasers = intensities between 12–60 mW/cm2 and doses
between 1 – 4 Joule per session; GaAlAs 780–860 nm
infrared pulse lasers = intensities between 30–200 mW/
cm2 and doses between 6 – 24 Joule per session.
These doses are based on optimal location-specific dose
ranges for osteoarthritis when the joint capsule is exposed
[9] and dosage recommendations from World Association
of Laser Therapy for pain relief[18].
Pulsed electromagnetic fields (PEMF), including shortwave therapy 
(SWT)
SWT (27 MHz)
Criteria for optimal dose: intensity between 14.2–76.7
Watts, pulse frequency between 100–800 Hz, treatment
time 20–30 minutes and doses between 17–138 kJoule
per session. These doses are based on a review of clinical
trial literature to determine optimal treatment procedures
and dose ranges for shortwave (27 MHz)[19].
PEMF other than SWT
Criteria for optimal dose: There is a lack of consensus of
optimal doses for intensity, so PEMF (other than SWT)
delivered at any intensity was included. Frequencies
between 10 and 200 Hz in line with those used in most
animal studies.
Electrical stimulation using surface electrodes (TENS)
Interventions which delivered electrical currents in the
milliampere range across the intact surface of the skin to
stimulate nerves innervating the knee joint (L4-5, S1;
[20]) were included providing a standard TENS device or
an interferential current stimulator was used [21]. Inter-
ventions using any other TENS-like device were excluded
because of the absence of a plausible physiological ration-
ale (e.g. microcurrent electrical stimulation, high voltage
pulse (galvanic) currents, high voltage TENS pens, tran-
scranial electrical stimulation, transcutaneous spinal elec-
troanalgesia (TSE), H-wave therapy and action potential
simulation [21]). No restrictions were placed on the elec-
trode types.
Criteria for optimal dose: a strong, near-noxious intensity,
pulse frequencies between 1–150 Hz, treatment time at
least 20 minutes per session in at least 5 sessions. These
doses are based on a meta-analysis with sub group analy-
sis for optimal dose for TENS [8].
Ultrasound therapy
Interventions which delivered mechanical vibration using
an ultrasound device at frequencies between 1.0–3.0 MHz
Criteria for optimal dose: intensity 0.1–3 W/cm2, contin-
uous or pulsed output, treatment time between 3–20 min-
utes and doses between 18–540 Joules per session. These
doses are based on those commonly reported in clinical
literature as optimal dose range has yet to be established
[22,23].
Static magnets
Criteria for optimal dose for this modality remain uncer-
tain, as does their anatomic location for placement on the
human body.
Placebo control groups
Reports that stated that they had included a placebo or
sham control were included. For LLLT, PEMF, TENS and
US reports were checked to ensure that the placebo/sham
intervention was inert in the form of an identical device
delivering no output (i.e. a dummy device). For acupunc-
ture, sham interventions were considered inert if they
used non-acupuncture points and superficial needling (≤
2 mm) or a specifically designed placebo needle. For sham
magnet therapy, identical-looking devices without any or
insignificant magnetic fields were considered.Page 3 of 14
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A criteria-list of methodological criteria was used for
assessment of trial quality [24]. Assessments of trial meth-
odology were made by two independent reviewers (JMB
and RABL-M). No specific cut-off limit for method scores
was pre-planned as criterion for exclusion.
Outcome measure extraction
The change in overall pain intensity between the active
intervention group and placebo was used. If more than
one attainable outcome measurement was obtained in the
first 4 weeks after treatment started, the time point corre-
sponding to the largest effect values was selected. If data
on overall pain intensity were missing, data were obtained
as a mean of the 5 items on the WOMAC pain subscale. If
WOMAC data were registered on non-continuous (cate-
gorical, Likert) scales, they were converted to 100 mm VAS
and checked against other subscales and overall WOMAC
score, as this has been found to have good internal con-
sistency [25]. If overall pain or WOMAC pain subscale
data were unavailable, pain on movement was used as
registered on a 100 mm VAS.
Statistical analysis of pain-relieving effect
Mean differences of change for intervention groups and
placebo groups and their respective standard deviations
(SD) were included in a statistical pooling. If variance data
were not reported as SDs, they were re-calculated algebra-
ically from the trial data of sample size and other variance
data such as p-values, t-values, standard error of mean, or
95% confidence intervals [CI]. As a control measure for
the stability of the small (n < 40) trials results, we substi-
tuted reported SDs (or other variance data) with the arith-
metic mean SD from the other trials with the same
intervention if SD was lower than the the arithmetic mean
[26].
Results were presented as weighted mean difference
(WMD) between intervention and placebo with 95% CI
in mm on VAS, i.e., as a pooled estimate of the mean dif-
ference in change between the treatment and the placebo
groups, weighted by the inverse of the variance for each
study (Fleiss 1993). A fixed effects model was applied.
Subgroup analysis
In order to give as precise effect estimates as possible, care
was taken to investigate discrepancies in trial samples and
interventions. The validity of heterogeneity tests is equiv-
ocal, and their results were only used to support sub-
grouping in cases where clinical and methodological
quality heterogeneity was evident. Heterogeneity was
tested using Q-values, and statistical significance was
defined at the 0.05 level for each intervention. To analyse
heterogeneity and effect size for each intervention, trials
were then subgrouped according to baseline pain, meth-
odological quality, adequate dosageand procedural rec-
ommendations for each physical agent using the criteria
listed previously (see criteria for optimal dose). Subgroup
analyses were also performed for results during the 5–12
week follow-up period, and for funding sources.
Publication bias analysis
Effect size plots were used as a graphical test in order to
detect possible publication bias [27,28].
Outcome measures
1) Best reduction in pain intensity during the first 4 weeks
after initiation of treatment scored on the subscale of pain
on the Western Ontario and McMaster Universities oste-
oarthritis index (WOMAC) [29] or on a 100 mm visual
analogue scale (VAS) for one, or the mean score of two or
more pain dimensions. Variance was calculated from the
trial data and given as 95% confidence intervals [95% CI]
in mm on VAS. Effect size within 4 weeks was defined as
a pooled estimate of the difference in change between the
mean of the treatment and the placebo control groups,
weighted by the inverse of the standard deviation for each
study, i.e. weighted mean difference of change between
groups.
2) Follow-up results at 1–12 weeks after end of treatment
were used for pain intensity (as described under 1) or cat-
egorical data of global health status. Improved global
health status was defined as any one of the following cat-
egories: "improved", "good", "better", "much improved",
"pain-free","excellent". The numbers of "improved"
patients were then pooled to calculate the relative risk for
change in health status. A statistical software package
(Revman 4.2) was used for calculations.
Results
Included studies
The literature search identified 770 potentially relevant
articles that were assessed by their abstracts. 590 abstracts
were excluded as irrelevant, and 180 full trial reports were
evaluated. 41 trials met our inclusion criteria. However,
five trials were subsequently excluded: One TENS-trial
with a positive result was excluded for not giving more
than a single treatment [30]. One LLLT trial with a nega-
tive result [31] and one trial with a positive result [32],
were excluded for not registering continuous pain data
and not giving separate data on knee osteoarthritis respec-
tively. One SWT trial was excluded for not presenting OAK
data separately [33], while another did not present pain
data [34] (Figure 1
Thirty-six randomised controlled trials satisfied all our cri-
teria for inclusion. Eleven trials were performed with
TENS (n = 425), 8 trials were performed with LLLT (n =
343), 4 trials were performed with manual acupuncturePage 4 of 14
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2007, 8:51 http://www.biomedcentral.com/1471-2474/8/51(MA). One of these 4 MA trials had been recategorised
because it used a weak electrical current at a comfortable
level (personal communication dr. Lao). Three trials met
our criteria for electro-acupuncture (EA). One trial was
performed with ultrasound therapy (n = 74), 7 trials were
performed with PEMF (n = 487) and two trials (n = 162)
were performed with static magnets (MA). A list of
included trials and their demographic data and their treat-
ment characteristics is summarised in Table 1.
Quality of extracted data
One small trial with MA and one small trial with TENS
reported unreasonably low SD values. For this reason,
their SDs were substituted with the arbitrary mean SD for
their intervention type [35,36]. All included trials
reported variance data which allowed for algebraic calcu-
lation of SDs. One trial reported median values rather
than mean values [37].
Patient sample demographics and baseline status
The median of the reported mean age of patients was 65.1
years and 69.9% were female. Patients with grades 2–4 of
roentgenological OA severity [38] were included. Eight
included trials did not report baseline pain. The mean
baseline pain scores on VAS were highest for LLLT (66.7
mm) and lowest for ultrasound therapy (53.0 mm) (Table
1).
Methodological quality
The mean methodological quality scores across all
included trials was 3.8 [range 1–5] out of a maximum
score of 5 on the Jadad scale. TENS had the lowest mean
score of 3.3 mainly due to the scores of 1 and 2 in two
cross-over trials with blinding problems [36,39]. PEMF
trials scored the highest mean value of 4.4. The most fre-
quent shortcomings in the included trials were: omitting
a description of the randomisation procedure, a lack of
concealed allocation to groups and/or inadequate blind-
ing. The results of the combined methodological quality
score is summarised for each therapy is summarised in
Table 1, and for each individual trial in Tables 2 to 8.
Short-term efficacy, best effect within 4 weeks
Six out of the 36 included trials did not provide continu-
ous data within 4 weeks from treatment start. Two of these
Table 1: Study characteristics and the distribution of trials for each intervention providing data within 4 weeks, included patients on 
active treatment, Q-values from heterogeneity tests, mean methodological scores, mean age of patients and baseline pain on a 100 
mm visual analogue scale (VAS). (*) One trial with electroacupuncture used too low electrical stimulation intensity according to 
optimal treatment criteria (Berman et al. 2004), and consequently was classified as manual acupuncture.
Type of intervention Total 
number of 
trials
Total number 
of patients
Number of 
trials with 
optimal 
treatment
Number of 
patients receiving 
optimal 
treatment
Mean 
methodological 
quality [range] 
(max score 5)
Mean age 
(years)
Q-values and p-
values in hetero-
geneity tests
Mean baseline 
pain on 100 
mm VAS †
TENS including IF 11 425 7 277 3.3 [1–5] 63.6 60.8 (p < 0.001) 63.8
Electro-acupuncture 3 242 3 242 3.6 [3–5] 62.9 1.1 (p = 0.58) 62.7
Manual acupuncture 4 691 4 691 3.9 [3–5] 66.1 4.5 (p = 0.34) 54.7
Low Level Laser therapy 8 343 5 222 3.5 [2–5] 66.9 36.4 (p < 0.001) 66.7
Pulsed electromagnetic fields 7 487 7 487 4.4 [3–5] 64.2 9 (p = 0.18) 63.3
Ultrasound 1 74 1 74 4 67.5 n.a. 53.0
Static magnets 2 172 2 172 4 [4] 65.6 1.9 (p = 0.22) 59.7
Total and means 36 2434 24 2165 3.8 65.1 62.9†
* = Mean † = Weighted mean
Quorum flow chartFigu e 1
Quorum flow chart. Quorum flow chart showing the 
selection process of the review.Page 5 of 14
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trial on MA [43].
The primary outcome, i.e. the overall best efficacy of the
different physical interventions within 4 weeks, is sum-
marised in Figure 2.
Secondary outcome – pain relief at follow-up
For the secondary outcome, pain relief at follow-up 0 – 12
weeks after end of treatment, there was a paucity of data
for manual acupuncture, TENS/IF and EA, which pre-
cluded a firm assessment of the efficacy for these interven-
tions. However, when estimates of the continuous and
categorical data of global improvement for TENS and IF
was combined, data suggest that most of the pain relieving
effect is retained for at least 2 weeks [44], or 4 weeks
[40,45] after the end of treatment (see also table 2). For
EA, the same tendency was seen, with global improve-
ment lasting 8 weeks after the end of treatment [46] (see
also table 3). For PEMF results were conflicting when
comparing efficacy at different time-points. Data for LLLT
indicated a slowly decreasing trend over time, which was
still giving a slight pain relief up to 8 weeks after treatment
was stopped [47,48] (see also table 5).
Table 3: Characteristics of included trials of electro-acupuncture for pain relief in patients with knee osteoarthritis
First author, 
publication 
year
Type No of patients 
on active 
therapy 
(n = 121)
Method 
quality
Treatment 
period 
(weeks)
Mean baseline 
pain (mm VAS)
Best mean difference 
(95% CI) of change over 
placebo (mm VAS)
Outcome assessment 
timepoints (weeks, best 
time point used in bold)
Sangdee-03 Maximal 
tolerable 
intensity
48 5 4 66.9 25.0 (15.2 to 34.8) 4, 8, 12
Vas-04 Maximal 
tolerable 
intensity
48 4 12 58.9 25.0 (13.4 to 36.6) 12
Yurtkuran-99 Maximal 
tolerable 
intensity
25 3 2 - 20.0 (14.1 to 25.9) 2
12 weeks Global 
improved
48 2.1 (1.1 to 4.1) Relative 
Risk
Best within 4 
weeks
73 4* 62.9† 21.3† (16.3 to 26.3) 3*
Total 121 4* 62.9† 21.9† (17.3 to 25.3) 3*
*Mean † Weighted mean
Table 2: Characteristics of trials of TENS for pain relief in patients with knee osteoarthritis
First author, 
publication year
Type No of patients on 
active therapy 
(n = 259)
Method 
quality
Treat-ment 
period (weeks)
Mean 
baseline pain 
(mm VAS)
Best mean difference 
(95% CI) of change over 
placebo (mm VAS)
Outcome time 
points (in weeks, 
max. effect in bold)
Adedoyin-03 IF 15 3 4 81.0 25.4 (8.2 to 42.6) 1, 2, 3,4
Cheing-02 TENS 16 4 2 - 8.4 (0.7 to 16.1) 2, 4
Cheing-03 TENS 30 3 2 50.3 32.2 (23.9 to 40.5) 4, 8
Defrin-05 IF 45 4 4 71.0 41.6 (33.4 to 49.8) 4
Fargas-Babjak-89 TENS 19 3 12 - 45.3 (11.7 to 78.9) 6, 12
Law-05 ALTENS/
TENS
27 4 2 57.3 29.7 (7.6 to 51.3) 2, 4
Lewis-84** TENS 29 3 3 - 7.0 (-5.6 to 19.6) 3
Lewis-94** TENS 28 1 3 - 4.9 (-8.4 to 18.3) 3
Smith-83 TENS 15 3 4 - dichotomous data only 4
Taylor-81** TENS 10 2 2 - 5.5 (-7.3 to 17.8) 2
Yurtkuran-99 ALTENS 25 3 2 - 20.0 (14.1 to 25.9) 2
Best within 4 
weeks, all trials
223 18.8 (9.6 to 28.1)
Best within 4 
weeks, optimal 
trials
156 22.2 (18.1 to 26.3)
8 weeks 30 8.3 (-1.1 to 17.6)
Global 
improvement 8 
weeks
15 1.8 (0.6 to 4.8) Relative 
Risk
Overall 259 3.3* 63.8† 2.8*
*Mean † Weighted mean – Not Available ** Trials with non-optimal treatmentPage 6 of 14
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First author, 
publication year
Intervention type, treatment 
period
No of patients on 
active therapy 
(n = 187)
Method 
quality
Mean 
baseline pain 
(mm VAS)
Best mean 
difference (95% 
CI) of change 
over placebo 
(mm VAS)
Outcome 
assessment 
timepoints 
(weeks, best time 
point used in bold)
Bulow-94** 25 mW, 830 nm, 2.25 J to 10 points 
3 times/week, 9 total sessions
15 2 82.0 8.0 (-10.8 to 26.8) 3, 6
Gøtte-95 12 mW, 904 nm, 12 J in 4 points, 3 
times/week 12 total sessions
20 3 69.0 25.0 (9.4 to 40.7) 4
Gur-03 10 mW, 904 nm, 2 or 3 J applied to 
2 points, 2–3 times week/10 total 
sessions
60 4 73.9 25.0 (18.9 to 31.1) 4, 8, 12
Hegedu-06 50 mW, 830 nm, 6 J applied to 8 
points, 2 times/week, total 8 
sessions
14 3 57.5 25.1 (2.5 to 47.7) 4, 6, 12
Nivbrant-92 4 mW 904 nm, 0.7 J in 3 points, 3 
times/week, 6 total sessions
15 4 67 19 (2.4 to 35.6) 2, 6
Stelian-92 2.7 mW and 25 mW 904 + 820 nm, 
1.3 J and 11.1 J in two points 10 
times/week, 20 total sessions
18 4 72.0 41 (25.4 to 56.6) 2, 10
Tascioglu-05** 50 mW 830 nm, 1.5 or 3 J in 5 
points, 5 times/week, 10 total 
sessions
20 3 66.5 -0.9 (-11.8 to 10) 3
Yurtkuran-06 ** 4 mW, 904 nm, 0.48 J in one 
acupoint (Sp9), 5 times/week, 10 
total sessions
25 5 - -0.7 (-18.6 to 17.2) 2, 12
Best within 4 weeks, 
all trials††
187 17.7 † (8.1 to 27.3)
Best within 4 weeks, 
optimal
142 24.2 (17.3 to 31.1)
6–8 weeks 104 15.5 (9.9 to 20.9)
12 weeks 99 12.3 (6.7 to 17.9)
Total 187 3.5* 70.3† 3*
*Mean † Weighted mean †† Random effects model used for calculation ** Non-optimal dose
Table 4: Characteristics of included trials of manual acupuncture for pain relief in patients with knee osteoarthritis
First author, 
publication 
year
Type No of patients on 
active therapy 
(n = 409)
Method 
quality
Treat-
ment 
period 
(weeks)
Mean 
baseline pain 
(mm VAS)
Best mean 
difference (95% CI) 
of change over 
placebo (mm VAS)
Outcome assessment 
timepoints (weeks, best 
time point used in bold)
Berman-04 TCM with "de Qi" 169 4 12 44.5 1.2 (-2.5 to 4.9) 4, 8
Molsberger-94 TCM with "de Qi 71 4 5 46.8 10.6 (0.1 to 21.3) 5
Takeda-94 TCM with "de Qi" 20 3 4 56.0 2.0 (-7.5 to 11.9) 4
Witt-05 TCM with "de Qi" 149 4 8 64.9 7.1 (0.2 to 14.4) 8
8 weeks 318 3.6 (0.2 to 7.1)
Total 409 3.8* 54.7† 1.3 † (-2.7 to 4.7) 4
*Mean † Weighted mean
Side-effects and adverse reactions
Six of the LLLT-trials [49,50,37,51,47,52] stated that treat-
ment was safe and/or that no adverse effects were
observed. One TENS trial reported 4 patient withdrawals
(14%) for unspecified adverse effects from TENS treat-
ment [39], and 1 TENS-trial reported mild skin reactions
after treatment [53]. Four TENS trials stated no withdraw-
als due to adverse events [44,45,54,55], while 2 trials did
not report on withdrawals or drop-outs. One withdrawal
(2%) was reported in each of the two EA trials due to
increased pain or unspecified cause [42,46], and no with-
drawals were reported in the last EA trial [55]. For MA,
14% of the patients reported mild side effects such as
small haematomas. None of the withdrawals in the 2 MA
trials were related to the therapy given trial [56,57]. For
PEMF, three trials [58-60] stated that no adverse events
had occurred. In 1 PEMF trial one patient withdrew after
reporting increased pain during treatment [61]. For SM, 2
patients (3%) reported dizziness or increased pain in 1
trial [62].
Subgroup analysis of methodological quality
Trials were generally of medium to high quality (≥ 3),
with the exception of one LLLT trial with method score 2
[37] and two TENS trials with method scores 1 [39] and 2
[36]. Exclusion of these trials from meta-analysesPage 7 of 14
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BMC Musculoskeletal Disorders 2007, 8:51 http://www.biomedcentral.com/1471-2474/8/51increased efficacy slightly for the two interventions in
question to 23.3 mm (95% CI 13.4 to 33.1) and 18.5 mm
(95%CI 8.5 to 29.2) for TENS and LLLT respectively.
Subgroup analysis of trials with optimal doses
Seven trials had to be excluded from the pre-planned sub-
group analysis with known optimal dose ranges for EA,
LLLT and TENS. One EA trial did not administer strong,
near-noxious electrical current intensity [57], and neither
did three TENS crossover trials [36,39,63]. For LLLT, one
trial with 904 nm delivering 0.48 J in one point, and one
trial with 830 nm administering 3J in five points had too
low doses and did not comply with WALT dosage recom-
mendations. The results of the subgroup analyses showed
that EA (21.3 mm [95%CI 16.3 to 26.3]), LLLT (24.2 mm
[95% CI 17.3 to 31.1]) and TENS (22.2 mm [95% CI 18.1
to 26.3]) offered similar and clinically relevant relevant
pain relief. The results are summarised in by trials in figure
3.
Clinical relevance of effects related to patient-centered 
outcomes
For optimal treatment with EA, TENS and LLLT, the com-
bined results indicated clinically relevant and important
effects when related to patient-centered outcomes (Figure
4).
Subgroup ananalysis of funding sources
Most of the trials were independently funded by unre-
stricted research grants from independent sources or the
hospitals where the trials were taking place. None of the
TENS/IF, LLLT, MA or EA trials were funded by for-profit
organisations. Three of the PEMF-trials were funded by
the supplier of the equipment [59-61], and excluding
Table 6: Characteristics of included trials of pulsed electromagnetic fields for pain relief in patients with knee osteoarthritis
First author, 
publication year
Intervention type, treatment 
sessions and period
No of patients 
on active 
therapy 
(n = 255)
Method 
quality
Mean baseline 
pain (mm VAS)
Best mean 
difference (95% CI) 
of change over 
placebo (mm VAS)
Outcome 
assessment 
timepoints 
(weeks, best time 
point in bold)
Callaghan-05 SWT, 3 sessions/week, 6 
sessions total, output 20 W in 20 
minutes, 400 Hz, treatment dose 
24 kJ
9 5 65.0 15.0 (-12.7 to 42.7) 2
Jacobson – 01 PEMF, 8 sessions, 1–8 Hz, 3 × 10-
7G
101 3 63.3 7.9 (0.8 to 15.4) 2, 4
Nicolakis-02 PEMF 30 min daily, 6 weeks, 40 
mT 1–3000 Hz
15 4 34.6 10.8 (-3.5 to 25.1) 6
Pipitone-01 PEMF 30 min daily, 6 weeks, 3–20 
Hz, <0.5 Gauss
34 5 - 2.0 (-5.8 to 9.7) 6
Thamsborg-05 PEMF, 2 h daily for 6 weeks, 10 
mV, 50 Hz
42 5 52.6 0.3 (-7.7 to 7.9) 2, 6, 12
Trock-93 PEMF, 15 Gauss, <30 Hz, 30 min 
3–5 times/week, total 18 sessions
14 4 76.5 31.0 (11.0 to 51.0) 2,4, 8
Trock-94 PEMF, 15 Gauss, <30 Hz, 30 min 
3–5 times/week, total 18 sessions
40 5 70.7 14.6 (0.9 to 28.3) 2, 4, 8
Best within 4 weeks 209 6.9† (2.2 to 11.6)
6 weeks 91 1.0 (-4.1 to 6.0)
8 weeks 47 19.8 (7.1 to 32.5)
12 weeks 42 -2.4 (-10.1 to 5.3)
Pooled 6–12 weeks 180 4.8 (-2.2 to 11.8)
Total 255 4.4* 63.7† 3.2*
*Mean † Weighted mean
Table 7: Characteristics of included trials of ultrasound therapy for pain relief in patients with knee osteoarthritis
First author, 
publication year
Type No of patients on 
active therapy (n = 74)
Method 
quality
Mean 
baseline pain 
(mm VAS)
Best mean 
difference (95% CI) 
of change over 
placebo (mm VAS)
Outcome assessment 
timepoints (weeks, 
best time point in bold)
Falconer-92 Maximal tolerable 0.1 
to 2.5 W/cm2. 2–3 
sessions/week, 12 
sessions total
74 4 53.0 n.s. 4
Total 74 4 53.0 n.s. 4
*Mean.
† Weighted meanPage 8 of 14
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to non-significance at 2.8 mm (95% CI – 3.7 to 9.2).
Publication bias
The graphical plots showed no obivious evidence for pub-
lication bias, but the number of included trials was small
(Figure 5, 6, 7 and 8).
Discussion
It seems that all but two of the included physical agents
(MA and ultrasound therapy), exhibit statistically signifi-
cant effects over placebo within 1–4 weeks, regardless of
what doses and treatment procedures were being used.
However, effect sizes for PEMF and SM, failed to reach the
mean threshold for "minimal perceptible clinical
improvement" for OAK as defined by Ehrich et al. [16]. It
cannot be ruled completely out that more studies may
contribute to optimise PEMF treatment procedure and
dosage, but at present MA, PEMF, US and SM cannot be
recommended for rapid pain relief in OAK management.
For TENS, the above findings are at odds with previous
reviews of TENS in chronic pain [64] and in chronic low
back pain [65], but not in knee osteoarthritis [66].
The picture for acupuncture is mixed, and most studies
with MA have been performed using fewer weekly treat-
ment sessions than the other interventions. Conse-
quently, the results at 4 weeks are similar to those of the
placebo groups, while the effect at 8 weeks is statistically
superior to placebo. In a systematic review of acupuncture
reviews, it has been argued that the evidence in favour of
acupuncture is weakened by lack of randomisation and
lack of assessor or patient blinding [67]. In this review, we
have only included randomised and double-blinded
(patient and assessor) trials, and the results are in line
with a recent review of acupuncture OAK [68]. However,
the clinical relevance of the MA effect in OAK remains
questionable, and the results infer that EA seems to be a
better choice in OAK management.
For LLLT, a Cochrane review has found limited evidence
in favour of LLLT in rheumatoid arthritis and inconclusive
evidence in osteoarthritis [69]. But we have previously
pointed out that the findings in osteoarthritis could be
caused by inherent methodological weaknesses [70] such
as lack of adequate dose-response analyses[71]. In line
with the dosage recommendations from World Associa-
Primary outcome – Forest plot for subgroups with optimal treatmentFigure 2
Primary outcome. Efficacy for each intervention measured 
at the end of treatment. Mean difference over placebo for 
pain measured on a 100 mm visual analogue scale (VAS) is 
shown as columns, and error bars indicate 95% confidence 
limits. The horizontal dotted lines indicate subjective thresh-
olds for mean perceptible improvement (lowest), mean slight 
improvement (middle) and mean important improvement 
(top). Abbreviations: LLLT (Low Level Laser Therapy), 
TENS/IF (Transcutaneous Electrical Nerve Stimulation and 
Interferential Currents), EA (Electro-acupuncture), PEMF 
(Pulsed Electro Magnetic Fields), MA (Manual Acupuncture), 
US (Ultrasound).
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Table 8: Characteristics of included trials of static magnets for pain relief in patients with knee osteoarthritis
First author, 
publication 
year
Type No. of patients on 
active therapy 
(n = 86)
Method 
quality
Treatment 
period (weeks)
Mean baseline 
pain (mm VAS)
Best mean 
difference (95% 
CI) of change 
over placebo 
(mm VAS)
Outcome 
assessment 
timepoints 
(weeks, best time 
point used in bold)
Hinman-02 Static magnets on 
knee"
22 4 2 38.8 8.6 (1.4 to 15.4) 2
Harlow-04 Static magnets on 
wrist (bracelet)
64 5 12 66.8 1.7 (-5.2 to 8.6) 4, 12
Best within 4 
weeks
86 5.1 (0.2 to 10.0)
12 weeks 64 6.5 (-0.6 to 13.6)
Total 86 3.8* 54.7† 4
*Mean † Weighted meanPage 9 of 14
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BMC Musculoskeletal Disorders 2007, 8:51 http://www.biomedcentral.com/1471-2474/8/51tion for Laser Therapy, the findings above suggest that 904
nm is only effective with doses of 2–12 Joules and 830 nm
with doses of 20–48 Joules when applied to 2–8 points
over the joint capsule.
The small sample size of some trials on EA, TENS and
LLLT may undermine the validity of our conclusions. It
has been argued that evidence for most interventions lack
sufficient statistical power to make valid conclusions [72].
The Oxford pain research group suggests that reasonably
robust conclusions can be be made from systematic
reviews including 200 patients and/or more than 4 trials
[67]. Cochrane reviews offer positive conclusions for
pharmacological interventions for pain based on the
inclusion of 40 patients for neck pain [73] and 185
patients for OAK [74]. The sample size for our total and
subgroup analyses for optimal treatment for EA, TENS
and LLLT met the criteria stated by the Oxford group (EA
n = 242, LLLT n = 222, TENS n = 272). Nevertheless, we
remain cautious in our conclusion until larger scale clini-
cal trials are available to verify the results. Methodological
trial quality also undermines review conclusions [36,63],
although the majority of trials on which our conclusions
rest, were of acceptable quality.
The biological rationales for the observed effects seem
somewhat clearer for EA, TENS and LLLT than for the
interventions that demonstrated lesser effects. EA and
TENS has been shown to inhibit ongoing nocicpetive
transmission at a segmental level and that this is dose-
dependent [75]. The EA-trials included in the review deliv-
ered electrical stimulation with needles placed in the
painful area, similar to that used for TENS. This is consist-
ent with established physiological principles whereby
stimulation in dermatomes and myotomes related to the
pain are likely to elicit segmental analgesia mechanisms.
It has been shown in experimental studies that electrical
stimulation by both needle and skin electrode can pro-
duce similar analgesic effects [76]. The observed similari-
ties between TENS and EA in effect size and time-effect
profiles after cessation of treatment, may be indices that
similar physiological mechanisms are being induced by
these two interventions. Adding the data from trials using
acupuncture to trials using electrical stimulation in the
Primary outcome – Forest plot for subgroups with optimal treatmentFigure 3
Primary outcome – Forest plot for subgroups with optimal treatment. Forest plot over 16 trials with optimal trea-
ment procedures and dose. Trials plotted on the right hand side of the middle line (WMD (fixed)) indicates a positive treat-
ment effect. The combined effect size for each intervention is placed below the trials, and combined overall effect of all 16 trials 
is plotted on the bottom.Page 10 of 14
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Effect size plot EA trialsFigure 7
Effect size plot EA trials. Effect/size plot for EA trials. 
Black circles indicate trials with optimal dose and treatment 
procedure. Effect over placebo is related to the x-axis and 
sample size is related to the y-axis.  
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Effect size plot TENS/IF trialsFigure 5
Effect size plot TENS/IF trials. Effect/size plot for TENS/
IF trials. Open circles indicate trials with non-optimal treat-
ment, and black circles indicate trials with optimal dose and 
treatment procedure. Effect over placebo is related to the x-
axis and sample size is related to the y-axis.
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Primary outcome – subgroupsFigure 4
Primary outcome – subgroups. Best efficacy for optimal 
dose and administration of each intervention within 4 weeks 
after treatment start. Mean difference over placebo for pain 
measured on a 100 mm visual analogue scale (VAS) is shown 
as columns, and error bars indicate 95% confidence limits. 
The horizontal dotted lines indicate subjective thresholds for 
mean perceptible improvement (lowest), mean slight 
improvement (middle) and mean important improvement 
(top). Abbreviations: LLLT (Low Level Laser Therapy), 
TENS/IF (Transcutaneous Electrical Nerve Stimulation and 
Interferential Currents), EA (Electro-acupuncture).
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Effect size plot LLLT trialsFigure 6
Effect size plot LLLT trials. Effect/size plot for LLLT tri-
als. Open circles indicate trials with non-optimal treatment, 
and black circles indicate trials with optimal dose and treat-
ment procedure. Effect over placebo is related to the x-axis 
and sample size is related to the y-axis.
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BMC Musculoskeletal Disorders 2007, 8:51 http://www.biomedcentral.com/1471-2474/8/51form of EA, did not increase effect size over TENS to any
appreciable extent.
During the last three years, controlled LLLT-trials have
found dose-dependent anti-inflammatory effects under in
vitro, in vivo, and in situ conditions [77,78]. Another pos-
sible explanation for the observed positive LLLT effects
may arise from local dose-dependent biostimulatory
effects on cell activity which have been observed in con-
trolled in vitro [79]and vivo [80] trials with lower, but over-
lapping, dose intervals.
The value of standardising treatment procedures and dos-
age in the treatment with physical agents is highlighted by
the finding that doses which work well in laboratory set-
tings also can be extrapolated to induce better pain reduc-
tion in the clinical subgroups of EA, TENS and LLLT-trials
with optimal treatment. But the heterogeneity of treat-
ment procedures, application techniques and doses still
call for careful interpretation of the results.
Until now, physical therapies have often been neglected
in editorials and reviews of treatments for OAK [81,82]
and this may have resulted in the under-utilization of
physical agents in OAK management [83]. The safety of
the physical therapies seems good as no serious adverse
events were reported in the 36 RCTs reviewed. The advan-
tage of physical agents is that they can be used in combi-
nation with drug therapy, thus reducing drug dosage and
adverse effects. There is also some evidence that effects
from adequately administered TENS, EA and LLLT remain
clinically relevant even 1–2 months after the end of treat-
ment. It may be difficult to directly compare the results of
trials of physical agents with those of pharmacological
interventions because of differences in the nature of the
placebo's used in the trials.
In the pharmacological literature publication bias in
favour of small trials with positive results has previously
been detected. There seems to be no support for this ten-
dency from asymmetry in the graphical plot [27]. On the
contrary, a small asymmetry towards publication bias in
favour of small trials with negative results seems to be
present for these physical interventions.
Exercise therapy, education and weight loss still remain
the cornerstones of long-term OAK management [81], but
our results suggest that EA, TENS and LLLT have potential
to become useful adjuncts in OAK pain management.
Conclusion
For patients with x-ray grade 2–4 and pain intensity levels
above 50 mm on VAS, an intensive regimen of 2–4 weeks
with TENS, EA or LLLT seems to safely induce statistically
significant and clinically relevant short-term pain relief.
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